In this commentary to the paper by Donadon V. et al (Clinical Medicine: Endocrinology and Diabetes. 2009;2:25-33.) the association and significance of insulin resistance with chronic liver disease are shortly reviewed and the molecular mechanisms underlying the diabetogenic and oncogenic potentials of advanced liver disease are summarized. Literature studies demonstrate that hepatocellular carcinoma (HCC) can be part of the natural history of NASH. HCCs in patients with features of metabolic syndrome as the only risk factor for liver disease have distinct morphological characteristics and mainly occur in the absence of significant fibrosis in the background liver. Moreover, data indicate that the presence of diabetes carries an approximately three to four-fold increased risk of HCC and such a risk is strongly increased by concurrent viral infections. Finally, the relationship between insulin resistance, steatosis and diabetes in NAFLD and HCV infection will be commented, along with the directions for future studies.
The Diabetogenic potential of Advanced Liver Disease
Insulin resistance (IR) is a concept popular among diabetologists who, historically, have contributed to its most explicit conceptualization in the last two decades. 1 During the same time period, however, IR has also become of great current interest among hepatologists. This is essentially the result of IR playing a key-role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD) 2 and being a cofactor of progression/impaired response to treatment in chronic hepatitis C.
3 Such close links between IR and two among the most common chronic liver disorders in western countries are likely to account for why diabetes almost invariably follows most chronic liver diseases. Moreover, they explain why cirrhosis, in particular, was depicted to be an overt diabetogenic condition a few years before Reaven had conceptualized the importance of IR in human disease. 4 Closing the circle, we now are aware that increasing stages of hepatic fibrosis are associated with increasing risks of developing type 2 diabetes via increasing levels of IR. The paper by Donadon 5 is further evidence for this pathogenic cascade of events.
The Oncogenic potential of Advanced Liver Disease is Influenced by IR
Not only does insulin regulate glucose metabolism, but it is also directly and indirectly involved in the risk of promoting the development of cancer at various extrahepatic organ sites such as colon, prostate, and pancreas. 6 There is strong epidemiologic evidence linking the metabolic syndrome (MS) and hepatocellular carcinoma (HCC); the molecular mechanisms sustaining hepatic carcinogenesis in those with IR, however, are not completely understood.
7
Primary liver cancer might result from activation of the tumor suppressor PTEN, a phosphoinositide phosphatase regulating the PI3K/Akt signaling pathways and the dysregulated expression and activity of which critically affects hepatic insulin sensitivity, triggers the development of NAFLD and participates in the molecular pathogenesis of HCC. 8, 9 The Hydroxymethyl-glutaryl-CoA inhibitors statins exert pleiotropic actions in liver physiology and particularly on cholesterol-related cell signalling pathways. 10 On this basis, the recent finding that statin use is associated with a significant reduction in the risk of HCC among patients with diabetes 11 indirectly suggests that metabolic pathways such as synthesis of bile acids, sonic Hedgehog, Kras, and the Rho family, p21 and p27 cyclin-dependent kinase inhibitors and fibrogenesis could be additional potential mechanisms involved in hepatocarcinogenesis in diabetics.
10,11

nAsH, cryptogenic cirrhosis and Hcc
Nonalcoholic steatohepatitis (NASH) is the most advanced histological form in the NAFLD spectrum. The association between NASH-cirrhosissometimes indistinguishable from cryptogenic cirrhosis-and HCC has been consistently confirmed by several studies summarized in Table 1 .
12-26 Such an association comes as no surprise given that cirrhosis of various etiologies is known to be a pre-cancerous condition 27 and NASH is indeed strongly associated with IR. 28 Overall, literature studies summarized in Table 1 demonstrate that HCC can be part of the natural history of NASH. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] HCCs in patients with features of MS as the only risk factor for liver disease have distinct morphological characteristics and mainly occur in the absence of significant fibrosis in the background liver. 22, 23 Awareness of these specific features of disease can be exploited to implement specific strategies aimed at obtaining earlier diagnoses and more effective treatment results.
26
Association of Diabetes, steatosis and Hcc
Population studies from Northern Italy have shown type 2 diabetic patients to have an increased risk of death from gastrointestinal diseases, particularly from liver cirrhosis after 5 years of followup and a higher risk of mortality from liver cancer after 10 years of follow-up, particularly in obese patients. 29 Such findings are strongly supported by several studies, summarized in Table 2 .
30-46
Data indicate that the presence of diabetes carries an approximatively three to four-fold increased risk of HCC. 32, 36, 45 Moreover, the metabolic risk of diabetes is strongly potentiated by concurrent viral infections. 31, 37, 44, 45 Given that steatosis is a sensitive barometer of metabolic health, the association of steatosis with HCC risk is also biologically plausible 35, 43 although a study contrasts with such a view. The patient with cirrhosis later died of hCC.
Cotrim hP 13
A patient with nASh-cirrhosis developed hCC after a 6-yr follow-up.
hCC can be part of the natural history of nASh.
Shimada 14 6 patients with nASh and hCC out of a series of 82 cases with nASh.
In patients with nASh-cirrhosis, the development of treatable hCC is sufficiently common to warrant regular screening for this grave complication.
Bugianesi 15 44/641 cryptogenic cirrhosisassociated HCCs, were identified. Of these, 23 were actively followed-up and compared in a case-control study with viral-and alcohol-associated hCC.
hypertriglyceridemia, diabetes, and normal aminotransferases are factors independently associated with hCC arising in cryptogenic cirrhosis, suggesting that hCC may represent a late complication of nASh-related cirrhosis.
regimbeau JM 16 18/210 hCC patients (8.6%) had no identifiable cause for the underlying liver disease.
The prevalence of obesity, diabetes, AST/ ALT ratio  1 , steatosis 20% and welldifferentiated tumors was significantly higher in patients with cryptogenic liver disease. Two cases of patients with hCC that developed into cryptogenic cirrhosis suggestive of nASh as background liver disease.
These cases progressed from nASh and fatty liver, respectively, to nASh-related cirrhosis, eventually developing hCC.
Guzman G 21
Three out of 50 patients with hCC. nAFLD may predispose patients to hCC in the absence of cirrhosis.
Paradis 22 hCC patients with features of MS as the only risk factor for liver diseases (n = 31) were compared to hCC patients with overt causes of CLD (n = 81) or without causes of CLD (n = 16).
hCCs in patients with features of MS as the only risk factor for liver disease have distinct morphological characteristics and mainly occur in the absence of significant fibrosis in the background liver.
hashimoto E 23 34 nASh patients with hCC were compared with 348 nASh without hCC.
Older age and advanced fibrosis were important risk factors for hCC. hCC was the major cause of mortality in nASh patients with advanced fibrosis. Regular screening for hCC is warranted for nASh patients with advanced fibrosis 
The Relationship Between Insulin Resistance, steatosis and Diabetes in nAFLD and HcV Infection
Early stages of both NAFLD and HCV infection share steatosis as a common histologic feature and IR is a physiopathologic feature of both liver diseases. Such findings have generated interest in the possibility of transferring knowledge from one disease to the other. 47 In the transgenic mouse model expressing HCV core protein, IR anticipates the development of steatosis. Overt diabetes only occurs once these animals gain weight as a result of a high-fat diet. A high level of tumor necrosis factor-alpha, which acts by disturbing tyrosine phosphorylation of insulin receptor substrate-1 and is a common finding also in human chronic hepatitis C, is considered to be one of the bases of IR in the transgenic mice.
48
Studies conducted by short-term high fat feeding rats support the hypothesis that hepatic steatosis leads to hepatic insulin resistance by stimulating gluconeogenesis and activating PKC-epsilon and JNK1, which may interfere with tyrosine phosphorylation of IRS-1 and IRS-2 and impair the ability of insulin to activate glycogen synthase. 49 Our group recently compared the predictors of IR in HCV and NAFLD. Data show IR to be independently asssociated with BMI and triglyceridemia in NAFLD; male gender and fibrosis in chronic HCV infection. 50 Collectively, these animal and human studies have relevant clinical implications. On the HCV side, eradication of viral infection with combined IFN+ Ribavirin regimens, which is associated with prevention of fibrosis, has resulted in the prevention of the development of diabetes 51 although this finding has not been invariably confirmed. 52 On the NAFLD side, these patients are often glucose-intolerant or diabetics either at the first diagnosis or during follow-up. [53] [54] [55] [56] Furthermore, in a study conducted in patients with type 2 diabetes, a weight loss of only approximately 8 kg resulted in improved basal and insulin-stimulated hepatic glucose metabolism associated with an 80% reduction in intrahepatic lipid content.
conclusions and Research Agenda
In conclusion, data reviewed here strongly support that advanced hepatic fibrosis is associated with diabetes and that diabetes increses the risk of developing HCC. Such a view is also confirmed in the study by Donadon.
5 Asssociation, however, does not prove causality. The paper by Donadon, owing to its cross-sectional design does not show which, between IR and HCC, comes first.
5 Prospective studies are, therefore, needed to address the issue whether those chronic liver disease patients who are more insulin-resistant are at an increased risk hCC patients with CC had similar impairments in liver function as patients with hCV infection. however, the hCC patients with CC had lower aminotransferase levels and higher platelet counts. HCC was significantly less likely to be diagnosed during surveillance and thus to be more advanced and less amenable to treatment compared with hCV patients. 161 patients with chronic hCV infection followed for up to 15 years.
Multivariate analysis identified hepatic steatosis, together with aging, cirrhosis, and no IFn treatment, as independent and significant risk factors for HCC.
yuan JM 36 295 hCC cases and 435 age-, gender-, and race-matched control subjects among hispanic and non-hispanic whites and blacks.
Subjects with a history of diabetes had an or of 2.7 for hCC compared with nondiabetic subjects. A synergistic interaction on hCC risk was observed between heavy alcohol consumption and diabetes, or between diabetes and viral hepatitis. In adjusted multiple logistic regression analyses diabetes was associated with a threefold increase in the risk of hCC. A significant positive interaction between hCV and diabetes was detected.
Kumar D
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The histological severity of steatosis was compared in the index liver biopsies of 25 patients with chronic hepatitis C who subsequently developed hCC with matched controls.
This is the only negative study reporting that hepatic steatosis does not augment the risk of hepatocarcinogenesis in patients with chronic hCV infection.
Lai MS 39 out of a prospective cohort of 54,979 subjects 5,732 individuals with T2D and 138 confirmed HCC cases were identified.
After controlling for confounders, the association between type 2 diabetes and incidence of hCC was only statistically significant for those being hCV negative and those having hypercholesterolemia.
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of developing HCC or if it is the presence of HCC per se that aggravates pre-existent IR. Moreover, given that most studies are based on patients with HCC rather than on diabetics, it is unclear whether a stricter metabolic control might be effective in preventing the development of HCC in these patients. 
